The FDA has rejected Biohaven’s request for approval of a neurological disorder therapy, prompting the biopharma to reprioritize its pipeline in order to shrink its annual R&D spend by 60%. After a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback